Skip to main content

Day: January 27, 2022

Wellbeing Digital Sciences’ Subsidiary KGK Science Forms Tactical Partnership with Nova Mentis

The Companies Plan to Jointly Submit a Psilocybin Clinical Trial Application to Health Canada VANCOUVER, British Columbia, Jan. 27, 2022 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), an evidence-based healthcare company focused on innovative clinical solutions, artificial intelligence-powered digital therapeutics and contract research, is pleased to announce that its wholly owned subsidiary, KGK Science Inc., (“KGK”), has formed a tactical partnership with Nova Mentis Life Science Corp. (“Nova”) (FSE: HN3Q) (OTCQB: NMLSF) to help develop Nova’s psychedelic psilocybin drug portfolio in Canada. Nova is a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders....

Continue reading

Pipedrive enhances service with Rackspace Technology Private Cloud management and UK data centre

NEW YORK, Jan. 27, 2022 (GLOBE NEWSWIRE) — Pipedrive, the global sales-first CRM and intelligent revenue management platform for small businesses, today announced the opening of a newly built Rackspace OpenStack private cloud environment in the UK, provided by Rackspace Technology® (NASDAQ: RXT), a leading end-to-end, multicloud technology solutions company. Now live, the private cloud environment brings Pipedrive closer to its European customers outside of the EU, including in the UK. The presence ensures Pipedrive is able to minimise response times and meet these territories’ security, compliance and data sovereignty requirements. In addition, Pipedrive will be enhancing its managed Amazon Web Services (AWS) environment to launch additional application regions via AWS, further expanding its reach for customers. Pipedrive, the...

Continue reading

Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease

LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) — Global Blood Therapeutics (GBT) today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has awarded a positive scientific opinion under the Early Access to Medicines Scheme (EAMS) for voxelotor, an oral once-daily tablet under review by the MHRA for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide. This positive opinion means that those patients living with SCD and meeting the eligibility criteria can gain early, pre-license access to voxelotor, while the MHRA completes its review of the Marketing Authorisation Application (MAA). The aim of EAMS is to grant early access to medicines that have received Promising Innovative...

Continue reading

UPM financial statements release 2021: Earnings back to strong pre-pandemic levels, refined completion plan for Uruguay project ready

UPM-Kymmene Corporation        Financial Statements Release 2021        27 January 2022 at 10:00 EET UPM financial statements release 2021:Earnings back to strong pre-pandemic levels, refined completion plan for Uruguay project ready Q4 2021 highlightsSales increased by 22% to EUR 2,673 million (2,188 million in Q4 2020) Comparable EBIT increased by 83% to EUR 461 million, 17.2% of sales (252 million, 11.5%) Operating cash flow was EUR 406 million (347 million) Net debt increased to EUR 647 million (56 million) and net debt to EBITDA ratio was 0.35 (0.04) The unprecedented energy market situation enabled UPM Energy to reach record earnings but added to the paper businesses’ costs The fair value of UPM’s sustainably managed forests increased due to higher wood volume, growth, and price estimates Refined completion plan for...

Continue reading

Nokia and Nordic Semiconductor to simplify IoT Standard Essential Patent licensing

Press Release Nokia and Nordic Semiconductor to simplify IoT Standard Essential Patent licensingNordic to give customers the opportunity to acquire licenses to Nokia’s cellular IoT technology when they purchase IoT hardware Innovative new arrangement will facilitate amicable and efficient licensing Licenses will be available to Nordic’s customers at the end device level27 January 2022 Espoo, Finland and Oslo, Norway – Nokia and Nordic Semiconductor announced today a pioneering new approach to licensing the use of cellular IoT Standard Essential Patents. Companies purchasing IoT hardware from Nordic will now be given the opportunity to acquire licenses to Nokia’s industry leading portfolio of cellular patents. This new agreement, which is the first of its kind, will simplify and speed up the Standard Essential Patent (SEP) licensing...

Continue reading

Prosafe SE: Ex-date for reverse share split today

Reference is made to press release published on 25 January 2022 notifying that the Extraordinary General Meeting had approved a reverse share split 1,000:1. Please be informed that the ex-date for the reverse share split is today, 27 January 2022. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 27 January 2022Prosafe SE For further information, please contact: Jesper K. Andresen, CEOPhone: +47 51 65 24 30 / +47 907 65 155 Stig Harry Christiansen, Deputy CEO and CFOPhone: +47 51 64 25 17 / +47 478 07 813 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Continue reading

Van Lanschot Kempen prepares additional covered bond programme

’s-Hertogenbosch/Amsterdam, the Netherlands, 27 January 2022 Van Lanschot Kempen is working on creating an additional covered bond programme with a soft bullet structure in 2022, under which any future covered bonds are expected to be issued. The new programme will allow further diversification of Van Lanschot Kempen’s debt investor base and funding profile. Media Relations: +31 20 354 45 85; mediarelations@vanlanschotkempen.comInvestor Relations: +31 20 354 45 90; investorrelations@vanlanschotkempen.com About Van Lanschot KempenVan Lanschot Kempen, a wealth manager active in Private Banking, Asset Management and Merchant Banking, aims to preserve and create wealth, in a sustainable way, for both its clients and the society of which it is part. Listed at Euronext Amsterdam, Van Lanschot Kempen is the Netherlands’ oldest independent financial...

Continue reading

Renault, Nissan & Mitsubishi Motors announce common roadmap Alliance 2030: Best of 3 worlds for a new future

Renault, Nissan & Mitsubishi Motors announce common roadmap Alliance 2030: Best of 3 worlds for a new futureThe 2030 roadmap focuses on pure electric vehicles and connected mobility. Aims to enhance usage of common platforms to reach 80% in 2026. Mitsubishi Motors to reinforce presence in Europe with two new models based on Renault best-sellers. To invest 23 B€ in the next five years to support its offensive strategy in electrification. With 35 new EV cars in 2030, proposes the largest global EV offer, based on the five common EV platforms. Nissan unveils an all-new EV based on the CMF–BEV Alliance platform to replace the Micra in Europe; vehicle planned to be manufactured at Renault ElectriCity, the electric industrial center in Northern France. Reinforces common battery strategy aiming to secure a global 220 GWh production...

Continue reading

Global Sleep Apnea Devices Market Size worth 13.10 Billion by 2028, at a CAGR of 7.1%

Global Sleep Apnea Devices Market Size [2022-2028] is expected to reach USD 13.10 billion by 2028, exhibiting a CAGR of 7.1% Pune, India, Jan. 27, 2022 (GLOBE NEWSWIRE) — The global sleep apnea devices market size is expected to reach USD 13.10 billion by 2028, exhibiting a CAGR of 7.1% during the forecast period. The growing cases of sleep apnea and surging geriatric population will have a tremendous impact on the market growth in the forthcoming years, states Fortune Business Insights, in a report, titled “Sleep Apnea Devices Market, 2021-2028.” The market size stood at USD 8.55 billion in 2020. Industry Development:August 2021: Vivos Therapeutics, Inc. received USFDA clearance for its mmRNA (modified mandibular Repositioning Nighttime Appliance) to treat mild to moderate obstructive sleep apnea (OSA).Get Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/sleep-apnea-devices-market-100708DRIVING...

Continue reading

Medical Swabs Market Size [2022-2028] | to Reach USD 4.59 Billion by 2028, Exhibiting a CAGR of 6.9%

According to the Fortune Business Insights, the Medical Swabs Market size is expected to reach USD 4.59 billion by 2028, exhibiting a CAGR of 6.9% Pune, India, Jan. 27, 2022 (GLOBE NEWSWIRE) — The global medical swabs market size is expected to reach USD 4.59 billion by 2028, exhibiting a CAGR of 6.9% during the forecast period. The increasing technological innovations in swab production will create lucrative opportunities for this market, states Fortune Business Insights in a report titled, “Medical Swabs Market, 2021-2028.” The market size stood at USD 2.67 billion in 2020 and USD 2.88 billion in 2021. Notable Development: April 2021: Mount Sinai Health System introduced Mount Sinai COVID-19 PCR Saliva Testing program to provide quick, noninvasive, and precise testing to support safety for businesses and leisure activities in...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.